Price$16.63-2.68 (-13.88%)
2026-03-042026-06-05
News · 26 weeks60-44%
2025-12-142026-06-07
Mix4090d
- Insider23(57%)
- SEC Filings9(23%)
- Other5(13%)
- Earnings3(8%)
Latest news
25 items- INSIDERChairperson & CEO Du Ying gifted 107,700 units of American Depositary Shares, decreasing direct ownership by 9% to 1,158,583 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- PRZai Lab Announces Changes to Senior Leadership TeamZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab over the past three and a half years and wish him well in his future endeavors," said Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. Zai Lab anticipates multiple clinical data readouts in 2026 for its lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary
- SECZai Lab Limited filed SEC Form 8-K: Leadership Update8-K - Zai Lab Ltd (0001704292) (Filer)
- INSIDERChairperson & CEO Du Ying exercised 261,092 units of American Depositary Shares at a strike of $1.74 and covered exercise/tax liability with 117,435 units of American Depositary Shares, increasing direct ownership by 13% to 1,266,283 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $1.74 and sold $1,986,875 worth of American Depositary Shares (100,000 units at $19.87) as part of a pre-agreed trading plan (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChief Legal Officer Edmondson Frazor Titus Iii sold $71,008 worth of American Depositary Shares (3,517 units at $20.19) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 19,849 units (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERChairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $1.74 and sold $2,003,044 worth of American Depositary Shares (100,000 units at $20.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Zai Lab Ltd (0001704292) (Issuer)
- PRZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has potential to be a first-in-class therapy for epNECs - Zoci NEC clinical program is advancing toward registration, with active engagement with Health Authorities underway Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the tre
- SECSEC Form 10-Q filed by Zai Lab Limited10-Q - Zai Lab Ltd (0001704292) (Filer)
- SECZai Lab Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Zai Lab Ltd (0001704292) (Filer)
- PRZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for VYVGART – Zocilurtatug pelitecan (zoci) delivered standout data at AACR 2026, with a 62.5% confirmed intracranial ORR in SCLC patients with brain metastases, and clinically meaningful activity (38.2% confirmed ORR) across epNECs; registrational DLLEVATE trial ongoing with enrollment expected to complete in the first half of 2027 – Collaborations with Amgen and Boehringer Ingelheim to evaluate zoci in combination with tarlatamab in SCLC and obrixtamig in SCLC and other NECs, posi
- SECSEC Form DEFA14A filed by Zai Lab LimitedDEFA14A - Zai Lab Ltd (0001704292) (Filer)
- SECSEC Form DEF 14A filed by Zai Lab LimitedDEF 14A - Zai Lab Ltd (0001704292) (Filer)
- PRZai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026- Company to host conference call and webcast on May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its first quarter 2026 financial results and provide recent corporate updates on May 7, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred): https://ed
- PRZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine CarcinomasZoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases; at 1.6 mg/kg dose, the confirmed iORR was 62.5% (10/16), including complete responses Encouraging activity was observed in extrapulmonary neuroendocrine carcinomas (NECs), with a 38.2% confirmed objective response rate Global Phase 3 trial ongoing in second-line-plus SCLC; first-line SCLC and neuroendocrine carcinoma programs advancing toward registrational phase in 2026 Investor conference call and webcast to discuss data being presented at AACR Annual Meeting 2026 and clinical trial
- SECSEC Form PRE 14A filed by Zai Lab LimitedPRE 14A - Zai Lab Ltd (0001704292) (Filer)
- PRBoehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine CarcinomasBoehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will test the combination of obrixtamig, a DLL3/CD3 T‑cell engager, with Zai Lab's zocilurtatug pelitecan (zoci), a DLL3‑targeting antibody–drug conjugate (ADC), to explore safety and potential increase in clinical benefit for patients. Ingelheim, Germany and Shanghai, China/Cambridge, Mass. – 15 April, 2026 – Boehringer Ingelheim and Zai Lab (NASDAQ:ZLAB, HKEX: 9688)) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/
- INSIDERSEC Form 4 filed by Smiley Joshua L4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERSEC Form 4 filed by Edmondson Frazor Titus Iii4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERSEC Form 4 filed by Du Ying4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERSEC Form 4 filed by Chen Yajing4 - Zai Lab Ltd (0001704292) (Issuer)
- INSIDERSEC Form 4 filed by Amado Rafael4 - Zai Lab Ltd (0001704292) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Zai Lab LimitedSCHEDULE 13G - Zai Lab Ltd (0001704292) (Subject)
- SECSEC Form 144 filed by Zai Lab Limited144 - Zai Lab Ltd (0001704292) (Subject)
- INSIDERSEC Form 4 filed by Edmondson Frazor Titus Iii4 - Zai Lab Ltd (0001704292) (Issuer)
ZLAB FAQ
7 questionsWhat does Zai Lab Limited do?
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer...Where does ZLAB stock trade?
Zai Lab Limited (ZLAB) is listed on NASDAQ.What sector and industry is ZLAB in?
Zai Lab Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zai Lab Limited go public?
Zai Lab Limited (ZLAB) completed its IPO in 2017.What are analysts saying about ZLAB?
Zai Lab Limited has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2025-08-25. Recent price targets range from $3610.00 to $4750.00.What companies are similar to ZLAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZLAB side-by-side with any of them on Quantisnow.How can I track ZLAB on Quantisnow?
Quantisnow aggregates Zai Lab Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZLAB to receive live email and push alerts on every new disclosure.